Cargando…

SARS-CoV-2 evolution and vaccines: cause for concern?

Detalles Bibliográficos
Autores principales:	Williams, Thomas C, Burgers, Wendy A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009632/ https://www.ncbi.nlm.nih.gov/pubmed/33524316 http://dx.doi.org/10.1016/S2213-2600(21)00075-8

Ejemplares similares

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations
por: Li, Pengfei, et al.
Publicado: (2022)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

Stroke after SARS-CoV-2 vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune escape
por: Yi, Chunyan, et al.
Publicado: (2022)

SARS-CoV-2 vaccines: fast track versus efficacy
por: Alkandari, Dana, et al.
Publicado: (2021)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
por: Shang, Weilong, et al.
Publicado: (2020)

Balancing risk and benefit of SARS-CoV-2 vaccines in children
por: Levin, Michael, et al.
Publicado: (2022)

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
por: Triccas, James A., et al.
Publicado: (2022)

Guillain-Barre syndrome related to SARS-CoV-2 vaccinations
por: Finsterer, Josef, et al.
Publicado: (2022)

SARS-CoV-2 vaccine strategies in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2023)

Stroke seven hours after SARS-CoV-2 vaccination
por: Fiorini, Ana Claudia, et al.
Publicado: (2023)

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity
por: Markov, Peter V., et al.
Publicado: (2022)

Respiratory syncytial virus after the SARS-CoV-2 pandemic — what next?
por: Mosscrop, Lucy G., et al.
Publicado: (2022)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

SARS-CoV-2 vaccination and phase 1 cancer clinical trials
por: Yap, Timothy A, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

SARS-CoV-2 and HIV-1 — a tale of two vaccines
por: Haynes, Barton F.
Publicado: (2021)

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine
por: Kennedy, Richard B
Publicado: (2022)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world
por: Garg, Pramod Kumar, et al.
Publicado: (2022)

Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes
por: Ong, Sean Wei Xiang, et al.
Publicado: (2021)

SARS-CoV-2 infection and cardiac arrhythmias
por: Dewland, Thomas A., et al.
Publicado: (2022)

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question
por: Marjot, Thomas, et al.
Publicado: (2021)

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
por: Bird, Sarah, et al.
Publicado: (2021)

Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?
por: Iversen, Patrick L, et al.
Publicado: (2021)

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
por: Anderson, Roy M, et al.
Publicado: (2020)

SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2022)

The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2
por: Li, Jing-Xin, et al.
Publicado: (2022)

SARS-CoV-2 vaccine-induced antibody levels: what lies beneath
por: Lassaunière, Ria, et al.
Publicado: (2022)

SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis
por: Di Filippo, Massimiliano, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_je96l0u8glak5jebtmgu8j5nk7